GMED und ADOT STRONG BUY - 500 Beiträge pro Seite

[oski]

ST. LOUIS, Jan. 20 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company" or "GenoMed")(National Quotation Bureau`s Pink Sheets Symbol GMED) announced today that the Company has secured an additional $900,000 in equity financing from Advanced Optics Electronics, Inc. (BULLETIN BOARD: ADOT) . This financing is separate and in addition to the up to $500,000 financing secured by the Company in October 2003 (see company press release of October 22, 2003).

Terms of the Agreement call for a capital investment into GenoMed of $900,000 in exchange for restricted common shares of GenoMed at a 25% discount to market. The financing Agreement will be available for public review within the Company`s next filings with the Securities and Exchange Commission (SEC) at http://www.sec.gov/ .

Dr. David Moskowitz, GenoMed`s CEO and Chief Medical Officer said, "I am pleased to report to the shareholders of our Company that we have secured financing that will allow the Company to accelerate our search for new disease genes, while also spreading the word about diseases we can manage based on the `master` disease gene we`ve already found."

Dr. Moskowitz continued, "The capital infusion will be spent mostly on genotyping, sample collection, and data analysis. We shall also commit some money to educating the public about being able to prevent 90% of kidney failure in this country, as well as significantly delay the progression of emphysema. Positive results for West Nile virus encephalitis, psoriasis, and late stage pancreatic cancer will be published soon. Trials are in progress for a number of diseases, including SARS and the flu."

Dr. Moskowitz ended by saying, "I believe this transaction is extremely fair. It limits the dilution to our existing shareholders as the Company moves forward
PR NEWSWIRE) GenoMed Launches Clinical Trial Against the Common Cold
GenoMed Launches Clinical Trial Against the Common Cold

ST. LOUIS, Jan. 26 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company"
or "GenoMed") (Pink Sheets: GMED) announced today that it has launched a free
clinical trial available to anybody with the common cold.
Symptoms of the common head cold consist of sore throat, runny nose, sinus
drainage, and occasionally fever, muscle aches, weakness, and fatigue. The
common cold causes billions of dollars of lost work. It is caused by a number
of viruses well-known to our species, including human coronaviruses. SARS is
caused by a coronavirus which is new to humans.
GenoMed has genomic epidemiologic evidence that autoimmune diseases such
as allergic sinusitis are associated with overactivity of angiotensin
I-converting enzyme, or ACE. The Company has been accumulating clinical
evidence that blocking the major product of ACE, which is a small eight amino
acid hormone named angiotensin II, can decrease inflammation in a number of
diseases, including viral disease. These diseases so far include alopecia,
psoriasis, fibromyalgia and chronic fatigue syndrome, and West Nile virus
encephalitis. GenoMed has already launched trials for influenza A, SARS, and
avian flu. It now launches an attack against the most common viral illness of
all, the common cold.
Using angiotensin II blockers to block the symptoms of a viral illness
such as the common cold has enormous clinical appeal, since nobody taking an
angiotensin II blocker or ACE inhibitor in the 25 years of their global use
has ever appeared to be immunocompromised. The same cannot be said for any
other immunomodulator in clinical use, such as steroids, which cause a number
of problems when used chronically. Not so with angiotensin II blockers.
GenoMed has already tested this patent-pending approach against West Nile
virus encephalitis, a viral scourge in which the people who die are the ones
with the most vigorous immune response. GenoMed`s patient outcomes for West
Nile virus encephalitis this past September were extremely encouraging: 7 out
of 8 patients had prompt disappearance of their symptoms within 12-48 hours
(24 hours on average). The only patient not to respond had chronic lymphocytic
leukemia, in which the immune response is known to be severely impaired. In
leukemia, white cells don`t work properly. But three patients over 70
recovered promptly. This age group has a 50% mortality from West Nile virus
encephalitis. GenoMed`s case series for West Nile virus encephalitis is
scheduled to be published in a special Pharmacogenomics issue of "Current
Topics in Medicinal Chemistry" later this year.
Said Dr. David Moskowitz, Chief Medical & Executive Officer for GenoMed,
"Our extremely positive experience with West Nile virus this past September,
and with autoimmune diseases like psoriasis and alopecia for over a year, have
shown us the utility of blocking angiotensin II in diseases with lots of
inflammation. We can`t prevent everybody from getting sick with a cold, but
our treatment may make people feel better more quickly compared with doing
nothing -- what`s called `supportive care only.`"
Continued Dr. Moskowitz, "As you can imagine, this will be a hard trial to
perform. We`ll be following how many people who enroll in our trial actually
come down with a full-blown head cold, how long they have to miss work or
school, and how bad their cold symptoms are on a scale of 1 to 10. We`ll ask
patients to rate their experience this winter against previous winters. We`ll
also try to get control information from other people in their household who
didn`t enroll in our trial. We`re looking for a major, clinically significant
change in their cold pattern, not a 10% difference, which will be undetectable
with this study design."
Dr. Moskowitz went on to say, "The Internet now makes it possible for
anybody to enroll in our free clinical trial at any time of day or night
anywhere in the world, simply by going to our website and clicking on `cold
trial.` They`ll have to enter their email address so that we can follow up
with them. We need to do this in order to be able to publish our case series
for the common cold as we`re already doing for West Nile virus. In return for
giving us their email address, people will be able to download the documents
they`ll need to show their physician in order to get started immediately on
our trial."
Dr. Moskowitz ended by saying, "We believe our approach may be ideal for
combating all viral diseases on a population-wide basis. The drugs we use are
safe in children and adults, so there`s virtually no risk if they`re used at
appropriate doses."
GenoMed thinks that it would make the most sense to begin using its
treatment when a patient feels a cold coming on, not after the patient feels
so miserable that s/he has to stay home from school or work. The drugs GenoMed
uses are safe enough to allow for their preventive use.
To volunteer for GenoMed`s free clinical trial against the common cold, go
to the home page at www.genomedics.com and click on "Common Cold Clinical
Trial


GMED news
*****
PR Newswire - January 26, 2004 09:41

KUALA LUMPUR, Malaysia, Jan 26, 2004 /PRNewswire via COMTEX/ -- PhenoMed Sdn Bhd, a development-stage disease management and medical-pharmaceutical therapeutic company, announces the initiation of its clinical trials program for infectious diseases.

"PhenoMed is announcing that it will begin collecting information from government agencies, physicians and individual patients interested in participating in the company`s clinical trials program. We are working closely with our US partner, GenoMed, Inc., and that company`s CEO and Chief Medical Officer, Dr. David Moskowitz, in helping to sign up interested parties," said Ezehan Reza Kamaluddin, PhenoMed`s interim Chief Operating Officer. "There is a worldwide need for disease management and targeted pharmaceutical therapeutics directed at infectious disease. Malaysia`s disease management needs are ever-present and PhenoMed wants to do all it can to help in meeting the country`s healthcare needs. The immediate concerns over avian flu in the region highlights this need."

PhenoMed`s US partner, GenoMed, believes it has discovered a way to accomplish the equivalent of vaccination against all viruses, a kind of "universal vaccine" against most viral diseases. The method involves blocking angiotensin II, an approach already known to be extremely safe from its use, for other purposes, in hundreds of millions of patients since 1978. This patent-pending method is presently under study by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, to test the Company`s compounds in tissue culture assays to evaluate potential activity against influenza (the flu) and SARS.

About PhenoMed, Sdn Bhd

PhenoMed is a development-stage disease management and medical- pharmaceutical therapeutic company, with its primary goal being the improvement of patient outcomes through the discovery and application of "genome-aware therapeutics(TM)". PhenoMed is building a network of physician and health services organizations to quickly expand its medical and therapeutic service offerings throughout the Asia-Pacific region. Founded in 2003, PhenoMed is a privately held company located in Kuala Lumpur, Malaysia. For more information about the company, please visit www.phenomed.net.

PhenoMed Contact:

Corporate Headquarters
Ezehan Reza Kamaluddin
Chief Operating Officer (Interim)
28-1, Level 1, Jalan 28/70A
Desa Sri Hartamas
50480 Kuala Lumpur, Malaysia
[e-mail]
www.phenomed.net


About GenoMed, Inc.

GenoMed, Inc. is a next generation disease management company whose mission is the improvement of patient outcomes through the identification of molecular pathways that cause disease. As first reported in a St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. GenoMed is currently conducting worldwide clinical trials for SARS and influenza A (the flu). In September of 2003, GenoMed obtained an 88% cure rate for this treatment approach against another lethal viral disease, West Nile virus encephalitis. These results will be published soon.

GenoMed Contact:
David W. Moskowitz MD, MA (Oxon.), FACP
314-977-0110
fax: [phone]
[e-mail]
www.genomedics.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE PhenoMed Sdn Bhd

Ezehan Reza Kamaluddin, Chief Operating Officer (Interim),
PhenoMed, [e-mail]; or David W. Moskowitz MD, MA (Oxon.), FACP,
GenoMed, [phone], fax: [phone], [e-mail]

http://www.genomedics.com

Copyright (C) 2004 PR Newswire. All rights reserved.

[oski]

GMED schon über 100% in einer Woche, weitere News werden erwartet
ADOT heute plus 22%
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Jan. 13, 2004--Advanced Optics Electronics Inc. (OTCBB:ADOT)

COLOR-CHEK, an innovative and cost-effective color speech processor under joint development with Advanced Optics Electronics Inc. and a JV partner, will be ready for demonstration of a production-quality prototype by Feb. 6, 2004. The subcontractor working with ADOT has provided management an update in order to prepare a demonstration for certain key institutional investment entities. Pricing of COLOR-CHEK is set at a very modest level to enable the vision impaired to make this purchase with or without insurance help.
Bald klingeln die Kassen

[oski]

GMED +7%
ADOT +15%

[oski]

[Lonesome]

Hat einer von Euch die e-mail Adresse von Adot`s IR? Habe ein paar Fragen deren Antworten längst fällig sind . . .

[oski]

Bald$$$$$$$$$$$$$$$$$$$

[freitag]

@OSki

Kennst Du noch GTEC ( Genesis Technology )? Da hat sich vieles geändert. Die haben jetzt SMS Lizens in China und und und....

http://www.wallstreet-online.de/si/community/board/search.ph…